TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Middle-School Based Primary Prevention Trial (HEALTHY)
Brief Summary: HEALTHY was a primary prevention trial conducted in 42 middle schools at 7 locations across the US to impact risk factors for type 2 diabetes in adolescents. Students were recruited at start of 6th grade (fall 2006) and followed to end of 8th grade (spring 2009). Half of the schools were randomized to receive an intervention that integrated four components: the school nutrition environment, physical education class activities, behavior change initiatives, and educational and promotional communications activities.


Options:
A: Arm Label: School based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: integrated program of nutrition, activity, behavior, and promotion | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: integrated program of nutrition, activity, behavior, and promotion; Assigned to Arm(s): School based intervention
B: Arm Label: Treatment Group; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity | Arm Label: Wait List Group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Physical Activity | Intervention Type: BEHAVIORAL; Name: Physical Activity; Assigned to Arm(s): Treatment Group, Wait List Group
C: Arm Label: Brief Motivational Counseling (BMC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief Motivational Counseling (BMC) | Arm Label: Brief Motivational Counseling Plus Phone Calls (BMC+Phone); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief Motivational Counseling (BMC), Behavioral: Brief Motivational Counseling Plus Phone Calls (BMC + Phone) | Arm Label: Brief Motivational Counseling Plus Home Visits (BMC+Home); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief Motivational Counseling (BMC), Behavioral: Brief Motivational Counseling Plus Home Visits (BMC + Home) | Intervention Type: BEHAVIORAL; Name: Brief Motivational Counseling (BMC); Assigned to Arm(s): Brief Motivational Counseling (BMC), Brief Motivational Counseling Plus Home Visits (BMC+Home), Brief Motivational Counseling Plus Phone Calls (BMC+Phone) | Intervention Type: BEHAVIORAL; Name: Brief Motivational Counseling Plus Phone Calls (BMC + Phone); Assigned to Arm(s): Brief Motivational Counseling Plus Phone Calls (BMC+Phone) | Intervention Type: BEHAVIORAL; Name: Brief Motivational Counseling Plus Home Visits (BMC + Home); Assigned to Arm(s): Brief Motivational Counseling Plus Home Visits (BMC+Home)
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention group | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention group; Assigned to Arm(s): Intervention group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Middle-School Based Primary Prevention Trial (HEALTHY)
Brief Summary: HEALTHY was a primary prevention trial conducted in 42 middle schools at 7 locations across the US to impact risk factors for type 2 diabetes in adolescents. Students were recruited at start of 6th grade (fall 2006) and followed to end of 8th grade (spring 2009). Half of the schools were randomized to receive an intervention that integrated four components: the school nutrition environment, physical education class activities, behavior change initiatives, and educational and promotional communications activities.


Options:
A: Intervention Type: BEHAVIORAL; Name: Nutritional and life style counseling; Assigned to Arm(s): N/A
B: Arm Label: School based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: integrated program of nutrition, activity, behavior, and promotion | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: integrated program of nutrition, activity, behavior, and promotion; Assigned to Arm(s): School based intervention
C: Intervention Type: BEHAVIORAL; Name: Fat and carbohydrate controlled diet; Assigned to Arm(s): N/A
D: Arm Label: A, Observational; Type: N/A; Interventions: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Middle-School Based Primary Prevention Trial (HEALTHY)
Brief Summary: HEALTHY was a primary prevention trial conducted in 42 middle schools at 7 locations across the US to impact risk factors for type 2 diabetes in adolescents. Students were recruited at start of 6th grade (fall 2006) and followed to end of 8th grade (spring 2009). Half of the schools were randomized to receive an intervention that integrated four components: the school nutrition environment, physical education class activities, behavior change initiatives, and educational and promotional communications activities.


Options:
A: Intervention Type: BEHAVIORAL; Name: Switch active lifestyles brought to you by MediaWise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Switch active lifestyles from MediaWise; Assigned to Arm(s): N/A
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Primary (Environmental) Weight Gain Prevention | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: Primary (Environmental) Weight Gain Prevention, Behavioral: Secondary (Behavioral) Weight Gain Prevention | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Primary (Environmental) Weight Gain Prevention; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: BEHAVIORAL; Name: Secondary (Behavioral) Weight Gain Prevention; Assigned to Arm(s): Arm 2 | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Arm 3
C: Arm Label: School based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: integrated program of nutrition, activity, behavior, and promotion | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: integrated program of nutrition, activity, behavior, and promotion; Assigned to Arm(s): School based intervention
D: Intervention Type: BEHAVIORAL; Name: Promotion of a healthy diet and physical activity; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Avoidance of Alcohol, Drugs, and Tobacco; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Cardiac Surgery
Brief Summary: Endothelin-1 is a powerful substance that may be involved in causing hemodynamic instability (problems related to unstable blood pressure) during and after open heart surgery. Tezosentan is an investigational intravenous drug that blocks the endothelin receptors. This clinical trial will assess the potential benefit of tezosentan compared with placebo in the treatment of patients undergoing open heart surgery with cardiopulmonary bypass (CPB). Treatment time is from the start of surgery up to 24 hours.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tezosentan | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tezosentan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): N/A
C: Arm Label: Bosentan for 16 weeks; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bosentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Bosentan for 16 weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Bosentan for 16 weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Macitentan; Type: EXPERIMENTAL; Interventions: Drug: Macitentan 10 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Macitentan 10 mg; Assigned to Arm(s): Macitentan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis
Brief Summary: In some participants with cystic fibrosis (CF), the disease is caused by a nonsense mutation (premature stop codon) in the gene that makes the cystic fibrosis transmembrane regulator (CFTR) protein. Ataluren has been shown to partially restore CFTR production in animals with CF due to a nonsense mutation. The main purpose of this study is to understand whether ataluren can safely increase functional CFTR protein in the cells of participants with CF due to a nonsense mutation.


Options:
A: Arm Label: Ataluren 4, 4, and 8 mg/kg, then ataluren 10, 10, and 20 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Arm Label: Ataluren 10, 10, and 20 mg/kg, then ataluren 4, 4, and 8 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Intervention Type: DRUG; Name: Ataluren; Assigned to Arm(s): Ataluren 10, 10, and 20 mg/kg, then ataluren 4, 4, and 8 mg/kg, Ataluren 4, 4, and 8 mg/kg, then ataluren 10, 10, and 20 mg/kg
B: Arm Label: Ivacaftor; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor | Arm Label: Observational; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): Ivacaftor
C: Arm Label: Ivacaftor; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): Ivacaftor | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 150 mg Ivacaftor q12h; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): 150 mg Ivacaftor q12h | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis
Brief Summary: In some participants with cystic fibrosis (CF), the disease is caused by a nonsense mutation (premature stop codon) in the gene that makes the cystic fibrosis transmembrane regulator (CFTR) protein. Ataluren has been shown to partially restore CFTR production in animals with CF due to a nonsense mutation. The main purpose of this study is to understand whether ataluren can safely increase functional CFTR protein in the cells of participants with CF due to a nonsense mutation.


Options:
A: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
B: Arm Label: VX-661/Ivacaftor combination; Type: EXPERIMENTAL; Interventions: Drug: VX-661/Ivacaftor, Drug: Ivacaftor, Drug: Placebo matched to Ivacaftor | Arm Label: Ivacaftor monotherapy; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor, Drug: Placebo matched to VX-661/ ivacaftor | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matched to VX-661/ ivacaftor, Drug: Placebo matched to Ivacaftor | Intervention Type: DRUG; Name: VX-661/Ivacaftor; Assigned to Arm(s): VX-661/Ivacaftor combination | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): Ivacaftor monotherapy, VX-661/Ivacaftor combination | Intervention Type: DRUG; Name: Placebo matched to VX-661/ ivacaftor; Assigned to Arm(s): Ivacaftor monotherapy, Placebo | Intervention Type: DRUG; Name: Placebo matched to Ivacaftor; Assigned to Arm(s): Placebo, VX-661/Ivacaftor combination
C: Arm Label: Lumacaftor/Ivacaftor (LUM/IVA); Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor, Drug: Ivacaftor | Intervention Type: DRUG; Name: Lumacaftor; Assigned to Arm(s): Lumacaftor/Ivacaftor (LUM/IVA) | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): Lumacaftor/Ivacaftor (LUM/IVA)
D: Arm Label: Ataluren 4, 4, and 8 mg/kg, then ataluren 10, 10, and 20 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Arm Label: Ataluren 10, 10, and 20 mg/kg, then ataluren 4, 4, and 8 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Intervention Type: DRUG; Name: Ataluren; Assigned to Arm(s): Ataluren 10, 10, and 20 mg/kg, then ataluren 4, 4, and 8 mg/kg, Ataluren 4, 4, and 8 mg/kg, then ataluren 10, 10, and 20 mg/kg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis
Brief Summary: In some participants with cystic fibrosis (CF), the disease is caused by a nonsense mutation (premature stop codon) in the gene that makes the cystic fibrosis transmembrane regulator (CFTR) protein. Ataluren has been shown to partially restore CFTR production in animals with CF due to a nonsense mutation. The main purpose of this study is to understand whether ataluren can safely increase functional CFTR protein in the cells of participants with CF due to a nonsense mutation.


Options:
A: Arm Label: Ataluren 4, 4, and 8 mg/kg, then ataluren 10, 10, and 20 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Arm Label: Ataluren 10, 10, and 20 mg/kg, then ataluren 4, 4, and 8 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Intervention Type: DRUG; Name: Ataluren; Assigned to Arm(s): Ataluren 10, 10, and 20 mg/kg, then ataluren 4, 4, and 8 mg/kg, Ataluren 4, 4, and 8 mg/kg, then ataluren 10, 10, and 20 mg/kg
B: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
C: Arm Label: Ataluren; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ataluren; Assigned to Arm(s): Ataluren | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Ataluren; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Intervention Type: DRUG; Name: Ataluren; Assigned to Arm(s): Ataluren

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Chemoprophylaxis for HIV Prevention in Men
Brief Summary: The purpose of this study is to determine whether daily use of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) can prevent HIV infection in men who also receive HIV counseling, condoms, and treatment for other sexually transmitted infections (STIs).


Options:
A: Arm Label: TDF/FTC; Type: EXPERIMENTAL; Interventions: Drug: daily TDF/FTC | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: daily TDF/FTC; Assigned to Arm(s): TDF/FTC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Tenofovir Disoproxil Fumarate (TDF); Type: ACTIVE_COMPARATOR; Interventions: Drug: Tenofovir Disoproxil Fumarate (TDF) | Arm Label: Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF); Type: ACTIVE_COMPARATOR; Interventions: Drug: Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tenofovir Disoproxil Fumarate (TDF); Assigned to Arm(s): Tenofovir Disoproxil Fumarate (TDF) | Intervention Type: DRUG; Name: Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF); Assigned to Arm(s): Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Atazanavir, Drug: Didanosine, Drug: Efavirenz, Drug: Emtricitabine/Tenofovir disoproxil fumarate, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nevirapine, Drug: Stavudine, Drug: Tenofovir disoproxil fumarate, Drug: Zidovudine/Lamivudine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Atazanavir, Drug: Didanosine, Drug: Efavirenz, Drug: Emtricitabine/Tenofovir disoproxil fumarate, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nevirapine, Drug: Stavudine, Drug: Tenofovir disoproxil fumarate, Drug: Zidovudine/Lamivudine | Intervention Type: DRUG; Name: Atazanavir; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Didanosine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Efavirenz; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Emtricitabine/Tenofovir disoproxil fumarate; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Lamivudine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Lopinavir/Ritonavir; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Stavudine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Tenofovir disoproxil fumarate; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Zidovudine/Lamivudine; Assigned to Arm(s): 1, 2
D: Arm Label: Truvada Arm; Type: EXPERIMENTAL; Interventions: Drug: Truvada | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Truvada; Assigned to Arm(s): Truvada Arm | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Single Country, Double-Blind, Randomized, 2-Arm, Parallel-Group Study, Evaluating Efficacy and Safety of Rimonabant 20 mg OD, With/Without Association of Nicotine Patch, as Aid to Smoking Cessation During 9-Week Period
Brief Summary: The primary objective is to compare the efficacy of rimonabant 20 mg OD fixed dose plus nicotine patch 21 mg OD with the combination rimonabant 20 mg OD fixed dose plus placebo patch on abstinence from smoking in cigarette smokers motivated to quit.

Secondary objectives are to evaluate the clinical and biological safety of rimonabant associated with nicotine replacement therapy during a 9-week treatment period and to evaluate the effect of the combination on weight and craving.


Options:
A: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine versus placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: nicotine versus placebo | Intervention Type: DRUG; Name: nicotine versus placebo; Assigned to Arm(s): A, B
B: Intervention Type: DRUG; Name: rimonabant (SR141716); Assigned to Arm(s): N/A
C: Arm Label: PROOF cohort; Type: N/A; Interventions: N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nasal Spray Nicotine Substitute (Experimental) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nasal Spray Nicotine Substitute (ad libitum) | Intervention Type: DRUG; Name: Nasal Spray Nicotine Substitute (Experimental); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Nasal Spray Nicotine Substitute (ad libitum); Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Red Cell Storage Duration and Outcomes in Cardiac Surgery
Brief Summary: The purpose of this study is to determine whether length of storage of RBC is related to postoperative morbid outcomes in patients undergoing cardiac surgery.


Options:
A: Arm Label: Standard of care; Type: ACTIVE_COMPARATOR; Interventions: Other: Blood transfusion | Arm Label: Arm B; Type: OTHER; Interventions: Other: Blood transfusion | Intervention Type: OTHER; Name: Blood transfusion; Assigned to Arm(s): Arm B, Standard of care
B: Arm Label: Prolonged RBC storage; Type: ACTIVE_COMPARATOR; Interventions: Biological: Prolonged RBC storage | Arm Label: Short RBC storage; Type: ACTIVE_COMPARATOR; Interventions: Biological: Short RBC storage | Intervention Type: BIOLOGICAL; Name: Prolonged RBC storage; Assigned to Arm(s): Prolonged RBC storage | Intervention Type: BIOLOGICAL; Name: Short RBC storage; Assigned to Arm(s): Short RBC storage
C: Arm Label: Biological; Type: EXPERIMENTAL; Interventions: Biological: Transfusion | Arm Label: Standard PRBCs; Type: EXPERIMENTAL; Interventions: Biological: Transfusion | Intervention Type: BIOLOGICAL; Name: Transfusion; Assigned to Arm(s): Biological, Standard PRBCs
D: Arm Label: Fresh not-leukocyte-reduced RBCs; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood transfusion | Arm Label: Fresh RBCs leukocyte-reduced; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood transfusion | Arm Label: RBCs with storage longer than 15 days; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood transfusion | Intervention Type: BIOLOGICAL; Name: Blood transfusion; Assigned to Arm(s): Fresh RBCs leukocyte-reduced, Fresh not-leukocyte-reduced RBCs, RBCs with storage longer than 15 days

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PEARL Intervention to Reduce Depression Among Adults With Epilepsy
Brief Summary: The purpose of this study is to test the effectiveness of a home-based depression treatment intervention called "Program to Encourage Active, Rewarding Lives (PEARL)". We hypothesize that over a 12-month period, compared to usual care, those receiving the PEARL intervention will show more improvement with their depression, have higher quality of life and function, and use fewer medical services.


Options:
A: Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: usual care | Arm Label: Standardized educational plan; Type: EXPERIMENTAL; Interventions: Other: Standardized educational plan | Intervention Type: OTHER; Name: Standardized educational plan; Assigned to Arm(s): Standardized educational plan | Intervention Type: OTHER; Name: usual care; Assigned to Arm(s): Usual care
B: Arm Label: Desiconnect; Type: EXPERIMENTAL; Interventions: Behavioral: Desiconnect, Other: CAU | Arm Label: Care-as-Usual (CAU) / wait list; Type: ACTIVE_COMPARATOR; Interventions: Other: CAU | Intervention Type: BEHAVIORAL; Name: Desiconnect; Assigned to Arm(s): Desiconnect | Intervention Type: OTHER; Name: CAU; Assigned to Arm(s): Care-as-Usual (CAU) / wait list, Desiconnect
C: Intervention Type: BEHAVIORAL; Name: Program to Encourage Active, Rewarding Lives (PEARL); Assigned to Arm(s): N/A
D: Arm Label: Deprexis; Type: EXPERIMENTAL; Interventions: Behavioral: Deprexis | Arm Label: Wait-list; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Deprexis, Behavioral: Wait-list | Intervention Type: BEHAVIORAL; Name: Deprexis; Assigned to Arm(s): Deprexis, Wait-list | Intervention Type: BEHAVIORAL; Name: Wait-list; Assigned to Arm(s): Wait-list

Answer: C